Suppliers and packagers for xarelto

xarelto

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Janssen Pharms	XARELTO	rivaroxaban	FOR SUSPENSION;ORAL	215859	NDA	Janssen Pharmaceuticals, Inc.	50458-575-01	1 BOTTLE in 1 CARTON (50458-575-01) / 1 GRANULE, FOR SUSPENSION in 1 BOTTLE	2021-12-01
Janssen Pharms	XARELTO	rivaroxaban	TABLET;ORAL	022406	NDA	A-S Medication Solutions	50090-3625-0	90 TABLET, FILM COATED in 1 BOTTLE (50090-3625-0)	2011-07-01
Janssen Pharms	XARELTO	rivaroxaban	TABLET;ORAL	022406	NDA	A-S Medication Solutions	50090-3625-1	12 TABLET, FILM COATED in 1 BOTTLE (50090-3625-1)	2011-07-01

Xarelto (Rivaroxaban) Supply Chain Analysis

Last updated: February 19, 2026

This report analyzes the key suppliers involved in the manufacturing and distribution of Xarelto (rivaroxaban), a widely prescribed anticoagulant. Understanding the supplier landscape is critical for assessing supply chain resilience, potential risks, and competitive dynamics within the broader anticoagulant market. The analysis focuses on active pharmaceutical ingredient (API) manufacturers and key excipient providers.

Who are the Primary Active Pharmaceutical Ingredient (API) Manufacturers for Xarelto?

Bayer AG, the originator of Xarelto, holds primary manufacturing responsibility for the API, rivaroxaban. However, generic versions of rivaroxaban are available, necessitating the identification of API suppliers for these generics.

• Bayer AG: As the innovator, Bayer maintains proprietary control and likely internal manufacturing or exclusive contract manufacturing agreements for the API used in its branded Xarelto product. Specific details regarding Bayer's API production sites and partners are proprietary.
• Generic API Manufacturers: Following patent expiry in various regions, numerous generic pharmaceutical companies have entered the rivaroxaban market. These companies rely on third-party API manufacturers. Key API suppliers for generic rivaroxaban include, but are not limited to:
  • Laurus Labs: This Indian pharmaceutical company is a significant supplier of APIs, including rivaroxaban, to the global generic market. Laurus Labs has stated capabilities in complex API synthesis, essential for rivaroxaban. [1]
  • Divi's Laboratories: Another prominent Indian API manufacturer, Divi's Laboratories, is known to produce rivaroxaban API. Their manufacturing capacity and regulatory approvals are key factors for generic drugmakers. [2]
  • Aarti Industries: This Indian diversified chemical company also supplies APIs, including rivaroxaban, to the pharmaceutical sector. Their integrated manufacturing processes are a competitive advantage. [3]
  • Granules India: Granules India is a significant player in the API market, producing a range of APIs for global pharmaceutical companies. Rivaroxaban is part of their product portfolio for generic formulations. [4]

The global API market, particularly for high-volume drugs like rivaroxaban, is concentrated in countries with established pharmaceutical manufacturing infrastructure and cost advantages, notably India and China.

What are the Key Excipients Used in Xarelto Formulations?

Xarelto is formulated into oral tablets. The inactive ingredients, or excipients, play a crucial role in tablet stability, dissolution, and bioavailability. While specific proprietary formulations may vary slightly, common excipients in rivaroxaban tablets include:

• Microcrystalline Cellulose: This is a common binder and filler in solid oral dosage forms. It provides bulk and aids in tablet compression.
• Croscarmellose Sodium: This is a disintegrant that helps the tablet break apart in the gastrointestinal tract, facilitating drug release.
• Hypromellose: A cellulosic polymer used as a film-coating agent, providing a protective layer, aiding swallowing, and potentially masking taste.
• Lactose Monohydrate: Often used as a filler and binder. However, its use is being scrutinized due to lactose intolerance in some patient populations. Manufacturers may opt for lactose-free alternatives.
• Sodium Lauryl Sulfate: A surfactant that can improve wettability and dissolution of poorly soluble drugs like rivaroxaban.
• Magnesium Stearate: A lubricant that prevents tablet ingredients from sticking to manufacturing equipment during compression.

Table 1: Key Excipients and Their Functions in Rivaroxaban Tablets

Excipient Category	Example Excipient	Primary Function(s)
Filler/Binder	Microcrystalline Cellulose	Bulk, tablet integrity
Disintegrant	Croscarmellose Sodium	Tablet breakdown, drug release
Coating Agent	Hypromellose	Protection, ease of swallowing
Filler/Binder	Lactose Monohydrate	Bulk, tablet integrity
Surfactant	Sodium Lauryl Sulfate	Enhanced dissolution
Lubricant	Magnesium Stearate	Prevents sticking during production

Suppliers of these excipients are typically specialized chemical manufacturers. The pharmaceutical grade of these excipients must meet stringent purity and quality standards set by regulatory bodies like the FDA and EMA. Major global excipient manufacturers include:

• Ashland: A global specialty chemical company providing a wide range of pharmaceutical excipients, including binders, disintegrants, and coating agents.
• Colorcon: A leading supplier of film coatings and excipients for solid oral dosage forms.
• BASF: A global chemical company that produces pharmaceutical ingredients and excipients, including microcrystalline cellulose and lactose.
• Evonik Industries: A specialty chemicals company with a broad portfolio of pharmaceutical excipients.

The sourcing of these excipients from multiple qualified suppliers is standard practice to ensure supply chain continuity and mitigate risks associated with single-source dependency.

What is the Geographic Distribution of Key Xarelto Suppliers?

The geographic distribution of Xarelto suppliers, particularly for APIs, is heavily concentrated in Asia, with India being a dominant hub.

• India: Home to a significant number of generic API manufacturers (e.g., Laurus Labs, Divi's Laboratories, Aarti Industries, Granules India) and excipient manufacturers. This concentration offers economies of scale but also presents geopolitical and regulatory risks.
• China: Also a major global supplier of APIs and chemical intermediates, including those used in pharmaceutical manufacturing. While specific Xarelto API suppliers in China are less publicly detailed for generics, the country's overall influence on the global API market is substantial.
• Europe: Originator manufacturing by Bayer AG likely occurs within its established pharmaceutical production facilities in Europe (e.g., Germany) and potentially other regions under contract. Excipient manufacturing is also distributed across Europe by major players like BASF and Evonik.
• North America: While not a primary hub for generic API manufacturing of rivaroxaban, North America has excipient manufacturers and is the primary market for the finished drug product. Contract manufacturing organizations (CMOs) in North America may also be involved in the final formulation and packaging of both branded and generic Xarelto.

This geographic concentration highlights the globalized nature of pharmaceutical supply chains and the reliance on specific regions for cost-effective production of key components.

What are the Regulatory Considerations for Xarelto Suppliers?

All suppliers involved in the Xarelto supply chain, from API manufacturers to excipient providers, must adhere to strict regulatory requirements.

• Good Manufacturing Practices (GMP): Regulatory bodies worldwide, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), mandate GMP compliance for all manufacturing facilities. This ensures product quality, safety, and consistency. [5]
• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory authorities. These confidential documents contain detailed information about the API manufacturing process, facilities, and quality control. Finished drug manufacturers can then reference these DMFs in their drug applications.
• Excipient Qualification: Pharmaceutical companies must rigorously qualify their excipient suppliers. This involves auditing manufacturing sites, reviewing quality control procedures, and ensuring the excipients meet pharmacopeial standards (e.g., USP, Ph. Eur.).
• ICH Guidelines: The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) provides harmonized guidelines on quality, safety, and efficacy. Suppliers must demonstrate compliance with relevant ICH guidelines, such as ICH Q7 (GMP for APIs) and ICH Q10 (Pharmaceutical Quality System). [6]
• Inspections and Audits: Regulatory agencies conduct periodic inspections of manufacturing facilities. Pharmaceutical companies also conduct their own audits of their key suppliers to ensure ongoing compliance.

Failure to meet these regulatory standards can result in product recalls, import alerts, and severe damage to a company's reputation and market access. For Xarelto, ensuring the quality and reliability of both API and excipient suppliers is paramount to maintaining patient safety and market authorization.

What are the Potential Risks and Mitigation Strategies for the Xarelto Supply Chain?

The global supply chain for Xarelto presents several potential risks:

• Geopolitical Instability: Concentration of API manufacturing in specific regions (e.g., India) makes the supply chain vulnerable to political unrest, trade disputes, or export restrictions.
  • Mitigation: Diversifying supplier bases across different geographic regions and establishing secondary suppliers for critical raw materials.
• Regulatory Changes: Evolving regulatory requirements or enforcement actions in key manufacturing countries can disrupt supply.
  • Mitigation: Proactive engagement with regulatory bodies, continuous monitoring of regulatory landscapes, and investing in robust quality management systems.
• Quality Control Issues: Batch failures or contamination at API or excipient manufacturing sites can lead to product shortages and recalls.
  • Mitigation: Rigorous supplier qualification, ongoing quality audits, and comprehensive testing of incoming materials. Implementing advanced analytics for predictive quality control.
• Supply Chain Disruptions (Natural Disasters, Pandemics): Events like the COVID-19 pandemic demonstrated the fragility of global supply chains.
  • Mitigation: Building inventory buffers for critical components, exploring localized or regional manufacturing options where feasible, and developing robust business continuity plans.
• Intellectual Property Disputes: While primary patents for Xarelto have expired in many regions, ongoing IP litigation related to manufacturing processes or specific formulations can pose risks.
  • Mitigation: Thorough IP due diligence and legal counsel.

Effective risk management requires a holistic approach that includes supply chain mapping, supplier performance monitoring, and proactive contingency planning.

Key Takeaways

• Bayer AG is the originator of Xarelto and controls its branded API supply.
• Generic rivaroxaban API is primarily sourced from manufacturers in India, including Laurus Labs, Divi's Laboratories, Aarti Industries, and Granules India.
• Key excipients such as microcrystalline cellulose, croscarmellose sodium, and hypromellose are supplied by global chemical companies like Ashland, Colorcon, BASF, and Evonik.
• The supply chain exhibits a geographic concentration of API manufacturing in India, presenting both cost advantages and potential geopolitical risks.
• Strict adherence to GMP and other regulatory standards is mandatory for all suppliers.
• Mitigation strategies for supply chain risks include supplier diversification, proactive quality management, and robust business continuity planning.

Frequently Asked Questions

1. Are there any U.S.-based API manufacturers for rivaroxaban? While a significant portion of generic API manufacturing is concentrated in India, U.S.-based pharmaceutical companies may utilize contract manufacturing organizations (CMOs) that operate within the U.S., or they may source APIs from multiple global suppliers, potentially including U.S.-registered facilities with international operations. Specific details on U.S.-based rivaroxaban API production are not publicly disclosed by all generic manufacturers.

2. How does Bayer ensure the quality of its API suppliers for Xarelto? Bayer, as the originator, likely maintains stringent internal quality control for its API production. If contract manufacturing organizations (CMOs) are used, Bayer would impose rigorous qualification processes, ongoing audits, and strict adherence to their proprietary manufacturing specifications and quality agreements, which exceed baseline regulatory requirements.

3. What is the impact of the concentration of API suppliers in India on Xarelto's global availability? The concentration in India provides cost efficiencies for generic Xarelto production, which can lead to more affordable drug prices. However, it also exposes the global supply chain to risks associated with regional disruptions, such as natural disasters, political instability, or regulatory enforcement actions specific to India.

4. Can a shortage of a specific excipient delay Xarelto production? Yes, a shortage of any critical excipient can significantly delay or halt the production of finished Xarelto tablets, even if the API is readily available. Pharmaceutical companies typically qualify multiple suppliers for each excipient to mitigate this risk.

5. What regulatory bodies oversee the API and excipient manufacturers for Xarelto? API and excipient manufacturers are overseen by the regulatory bodies of the countries in which they operate and the countries to which they supply products. This includes the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), India's Central Drugs Standard Control Organisation (CDSCO), and other national health authorities. Manufacturers must comply with the regulations of each market they serve.

Citations

[1] Laurus Labs. (n.d.). Active Pharmaceutical Ingredients. Retrieved from https://www.lauruslabs.com/api/

[2] Divi's Laboratories. (n.d.). Product List. Retrieved from https://www.divis.com/product/product-list

[3] Aarti Industries. (n.d.). API Product Portfolio. Retrieved from https://www.aarti-industries.com/api-product-portfolio

[4] Granules India. (n.d.). APIs. Retrieved from https://www.granulesindia.com/apis

[5] U.S. Food & Drug Administration. (n.d.). Good Manufacturing Practice (GMP). Retrieved from https://www.fda.gov/drugs/guidance-compliance-regulatory-information/good-manufacturing-practice-gmp

[6] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). Harmonised ICH Guidelines. Retrieved from https://www.ich.org/products/harmonised-guidelines